Airway diseases
Oral presentation
Bronchiectasis heterogeneity: assessing the endotypes
Aims : This session is built from abstracts published on the ERS Congress platform from 23 August, in a PowerPoint format with a pre-recorded audio narration. The live session is scheduled from September 5-7 and each presenter will have a 5-minutes live, slide show presentation followed at the end of the session by 30-minutes general discussion.
Methods :
Epidemiology, Pulmonary function testing, General respiratory patient care, Cell and molecular biology
16:30
Introduction
1
OA1305
16:35
The bronchiectasis ‘bacteriophagome’
M. Mac Aogáin(Dublin, Ireland)
COI
2
16:40
Characterisation of eosinophilic bronchiectasis: A European multicohort study
A. Shoemark(Dundee (Angus), United Kingdom)
COI
3
16:45
The microbiology of stable bronchiectasis: data from the EMBARC bronchiectasis registry
M. Shteinberg(Haifa, Israel)
COI
4
16:50
Changes in sputum bacterial density in people with bronchiectasis: BRONCH UK Study data
Z. Alfahl(Galway, Ireland)
COI
5
16:55
Sputum neutrophil elastase and inhaled antibiotic response in bronchiectasis: a post-hoc analysis of the ORBIT-4 trial
H. Abo-Leyah(Sheffield, United Kingdom)
COI
6
17:00
Mapping inflammatory endotypes of bronchiectasis associated with impaired mucociliary clearance
M. Bottier(London, United Kingdom)
COI
7
17:05
Inhaled corticosteroids use in patients with bronchiectasis: Data from the EMBARC registry
P. Goeminne(Bornem, Belgium)
COI
8
17:10
Salivary proinflammatory cytokines and airway bacterial infection in Bronchiectasis
L. Perea(Barcelona, Spain)
COI
9
17:15
Immunometabolic markers and the sputum microbiome in bronchiectasis
Y. Giam(Dundee (Angus), United Kingdom)
COI
10
17:20
Late Breaking Abstract - The respiratory tract of patients with antibody deficiency on immunoglobulin replacement is characterised by inflammation and dysbiosis despite adequate levels of sputum IgG
A. Schnell(Bern, Switzerland)
COI
11
17:25
Discussion
12
OA1316
. . .
